Tissue Regenix has reported FY24 results to December 2024, which reflect the previously announced divestment of the GBM-V division. Revenues were $28.6m for the year, up 9% YoY. Revenue growth was lower than historical levels due to impacts in the Released Donor Tissue and the amnion product lines, within the BioRinse division. Despite the lower growth, the company significantly improved its adjusted EBITDA to $1.9m from $0.7m, supported by cost control, particularly in the BioRinse division. Th ....
